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Introduction
The acute phase response is considered a part of in-
nate host defense system, which is responsible for the 
survival of the host during the critical early stages of 
attack1. Inflammatory, infectious, immunologic, neo-
plastic conditions and other injuries, such as surgery, 
can stimulate thse response, which includes changes 
in the concentrations of determined plasma proteins, 
called acute phase proteins (APPs). There are negative 
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Ceruloplasmin (Cp) is a positive acute phase protein, responsible for the transport of copper and protection of cells 
and tissue against oxidant compounds. The aim of this study was to evaluate Cp concentrations at diagnosis and during 
chemotherapy in dogs with multicentric lymphoma (ML). Cp was measured using orto dianisine technique, in two 
groups of dogs: ten healthy dogs (control) and 13 dogs with ML. All dogs were submitted to chemotherapy. Dogs with 
signs of concurrent disease or that have been previously treated with prednisone were excluded from the study. Cp 
measurement was done before treatment and once a week, during the first month of chemotherapy, and each 3-week 
intervals until the relapse for dogs with ML, and until the 16th week in control dogs. ANOVA test followed by multiple 
Tukey’s tests were used to compare the groups. There was no difference between the mean of Cp concentration in dogs 
with ML at the diagnosis when compared to healthy dogs (p > .05). Levels of Cp decreased significantly at 4th week when 
compared to the first week, but Cp increase was not observed at the relapse. At all other times during the treatment, 
Cp concentrations for dogs with lymphoma were not significantly different from controls submitted to chemotherapy. 
As conclusion, Cp levels in ML at diagnosis were similar to healthy dogs, decreased when lymphoma remission was 
achieved and there was no change at the relapse.
Keywords: Ceruloplasmin. Lymphoma. Dogs. Acute phase protein.
Resumo
Ceruloplasmina (Cp) é uma proteína positiva de fase aguda, responsável pelo transporte de cobre e proteção das células 
e tecidos contra compostos oxidantes. O objetivo deste estudo foi avaliar as concentrações de Cp no momento do 
diagnóstico e durante a quimioterapia em cães com linfoma multicêntrico (LM). Cp foi mensurada utilizando-se a 
técnica da orto dianisina em dois grupos de cães: dez cães sadios (controle) e 13 cães com LM. Todos os cães foram 
submetidosàa quimioterapia. Cães com sintomas de doenças intercorrentes ou que haviam sido previamente tratados 
com prednisona foram excluídos do estudo. Cp foi mensurada antes do início do tratamento e uma vez por semana 
durante o primeiro mês de quimioterapia e depois a intervalos de três semanas até a recidiva.para cães com LM, e até 
16 semanas nos cães do grupo controle. ANOVA seguida pelo teste de Tukey foi usada para comparar os grupos. Não 
houve diferença entre a media das concentrações de Cp em cães com LM ao diagnóstico quando comparados aos 
cães sadios (p > 0.05). Os níveis de Cp diminuíram significativamente na quarta semana de tratamento comparado ao 
momento do diagnóstico. Aumentos nas concentrações de Cp não foram observados na recidiva. Durante o tratamento, 
as concentrações de Cp em cães com linfoma não diferiram daquelas observadas nos animais do grupo controle 
submetidos à quimioterapia. Concluiu-se que os níveis de Cp nos cães com LM ao diagnóstico foram similares aos cães 
sadios, diminuiu quando se obteve a remissão e não se alterou na recidiva da doença.
Palavras-chave: Ceruloplasmina. Linfoma. Cães. Proteínas de fase aguda.
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APPs, which decrease in concentration during the re-
sponse (e.g albumin) and positives APPs, that increase 
during acute phase response (e.g ceruloplasmin)2.
Positive APPs are synthesized mainly by hepatocytes 
under stimulation of inflammatory cytokines such as 
IL-1, IL-6 and TNF- α. and represent a very fast and 
nonspecific response that occurs in many cases before 
clinical signs3. Production and response of APsS varies 
depending on the species and biological characteristics 
of the protein. Ceruloplasmin (Cp) is a positive alfa 2 
glycoprotein in dogs4 that is responsible for the trans-
port of copper and protection of cells and tissue against 
oxidant compounds, generated by phagocytes in the 
course of clearing microorganisms of tissue debris2.
Multicentric lymphoma (ML) is a common neopla-
sia in dogs, and systemic chemotherapy is indicated 
for long-term5. Despite the fact that ML is more sen-
sitive to chemotherapy than other tumors, treatment 
is generally palliative and the objective is to achieve 
remission for extensive periods6,7. Several protocols 
utilizing combinations of chemotherapeutic agents 
such as prednisone, vincristine, cyclophosphamide 
doxorubicin and metotrexate are used and there is no 
consensus regarding the best treatment considering 
efficacy, remission and survival times then, relapse is 
common during chemotherapy and usually requires 
drug regimen modifications5,8 then, chemotherapy 
changes before clinical relapse could help to control 
cancer progression.
In humans, some APPs has been used as a prognos-
tic factor for lymphoid neoplasias, as well as for mon-
itoring cancer remission and relapse1,9,10,11. In dogs, 
some acute phase proteins were studied for monitor-
ing diseases and cancer such as haptoglobin, C reac-
tive protein and serum amyloid A3,12,13  with variable 
results, but there are no studies about the use of Cp 
for monitoring canine lymphoma. The purpose of 
this study was to evaluate the levels of Cp in dogs with 
multicentric lymphoma undergoing chemotherapy 
and if there are changes during the treatment.
Material and Method
Ten healthy dogs anen13 dogs with ML were in-
cluded in the study. The experimental protocol was 
approved by the Bioethics Committee of the Univer-
sity of São Paulo, School of Veterinary Medicine and 
Animal Science, in São Paulo, Brazil.
For the ten healthy dogs, results of clinical examina-
tion, CBC, serum biochemical profile (urea nitrogen, 
alanine aminotransferase and alkaline phosphatase 
activities, total protein, albumin, calcium and phos-
phorus) and urinalysis were unremarkable. Animals 
with signs of disease or any abnormality in the tests 
performed were excluded from the study. These ani-
mals (university-owned animals) were included in the 
Control group (n = 10) and submitted to chemother-
apy for 16 weeks, to determine the effects of chemo-
therapy on serum Cp concentrations.
Thirteen dogs, all private-owned patients with 
multicentric lymphoma, diagnosed on the basis of 
cytologic examination of a fine-needle aspiration of 
an enlarged, peripheral lymph node were studied. 
Physical examination, CBC, serum biochemical pro-
file, urinalysis, thoracic radiography and abdominal 
ultrasonography were performed in all dogs, and the 
dogs were classified as having stage IV or V multi-
centric lymphoma. Animals with signs of concurrent 
disease, localized infection, previous undergone che-
motherapy or that were treated with prednisone were 
excluded from the study, as well as dogs presenting 
complications during treatment. Response was clas-
sified as complete remission (CR) (ie, disappearance 
of all solid tumors and clinical signs), partial remis-
sion (PR) (ie, ≥ 50% decrease in the size of tumor), 
or no response (ie, < 50% reduction in tumor size). 
Only animals with complete or partial remission were 
included in the study.
The dogs (control and lymphoma groups) were 
treated under CVP or VCMA protocol. CVP pro-
tocol consisted of cyclophosphamide (250 mg/m2, 
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PO), vincristine (0,75 mg/m2, IV) and prednisone 
(40 mg/m2, q 24 h, PO), at week 1. Subsequently, the 
dogs received vincristine once a week for thre3 weeks 
and then at 3-week intervals; cyclophosphamide at 
3-week intervals and prednisone (20 mg/m2) on al-
ternate days until relapse. VCMA protocol consisted 
of administration of vincristine consisted of adminis-
tration of vincristine (0.75 mg/m2, IV) during weeks 
1 and 3; cyclophosphamide (250 mg/m2, PO) during 
week 2, and  administration of methotrexate (0.8 mg/
kg [0.36 mg/lb], IM) during week 4. A single dose of 
l-asparaginase (10,000 U/m2, SC) was given on day 1. 
This monthly schedule was maintained until relapse 
was detected. A CBC was performed before every 
treatment was administered, and chemotherapy was 
delayed if the neutrophil count was < 2,500 cells/μL.
In ten healthy dogs undergoing chemotherapy, 
blood samples were collected at week 1 (prior to 
treatment), 2, 3, 4, 7, 10, 13 and 16. In the dogs with 
lymphoma, the samples were collected before drug 
administration at weeks 1 (prior to treatment), 2, 3 
and 4, at disease relapse, when the enlargement of the 
lymph nodes was detected. For all groups, serum was 
harvested and frozen at -70 ºC until assayed for Cp 
concentration. 
Serum Cp concentration was determined by man-
ual technique of Schonsinsky, Lehmann and Beeler14, 
measuring the oxidative activity for this protein using 
orto dianisidine.
Data for Cp concentrations were analyzed by use of 
repeated-measures ANOVA following Tukey–Kram-
er Multiple Compariosns Test. Values o  p < 05 were 
considered significant.
Results
Five CVP Control dogs ranged from to2 to for4 
years of age and weighed between 12 and 23 kg, being 
for4 males (all intact) an 1one neutered female. Five 
VCMA Control dogs ranged from to2 to for4 years of 
age, and weighed between 12 and 19 kg, being thre3 
males (neutered) and to2 neutered female. 
Seven dogs with lymphoma assigned to CVP proto-
col ranged from to2 t10ten years old (mean 5,5 years) 
and weighed between 14 and 42 kg . Two were males 
(all intact) and fie5 were females (one neutered), being 
sx6 purebred and oe1 mixed-breed dogs. Six VCMA 
Lymphoma dogs ranged fro 3three t 8eight years old 
(mean 5,1 years old) and weighed between sx6 and 35 
kg . Five were females (none neutered) and one was 
male, being all purebred. 
Of the seven dogs with lymphoma assigned to CVP 
protocol, fie5 achieved a complete remission an 2two 
partial remission. Median of survival times was 257 
days (SD = 105 days, range 75 to 390 days), mean time 
of remission  was 104 days, (SD = 58 days, range 47 
to 196 days) . In the dogs with lymphoma receiving 
VCMA protocol, all six dogs had a complete remis-
sion. Median of survival times was 297 days (SD = 131 
days, range 109 to 498 days), mean time of remission 
was 167 days (SD = 85 days, range 56 to 267days). 
Statistical analysis showed that there was no differ-
ence in relation to Cp levels, due to use of different 
treatment protocols. This is justified because Cp is not 
influenced by the use of corticoids. After this result, 
the groups were studied considering only the condi-
tion of control (healthy) and lymphoma. 
For dogs with lymphoma, mean Cp at the first week 
(prior to treatment) was 21,67 U/L (range 10 to 31,87 
U/L) and there was no difference when compared to 
healthy dogs, that presented Cp mean of 17,85 U/L 
(range 11,87 to 29,92) (p = 0,3868), table 1.
Considering the analysis of Cp concentrations in 
dogs with ML prior to treatment, on the 4th week (re-
mission evaluation) and at the moment of relapse, 
there was a significative difference. The levels of Cp 
concentration decreased in the remission period 
when compared to the values observed at the diag-
nosis. There was no increase during the treatment, 
including the moment which the relapse was detected 
Braz. J. Vet. Res. Anim. Sci., São Paulo, v. 47,  n. 6,  p. 477-482, 2010
480
(p > .05). The Cp levels observed in the control group, 
undergoing chemotherapy at 4th week was higher 
when compared to ML group.
Discussion
The study of acute phase proteins and their associa-
tion with lymphoma relapse arose from the needing 
to find an early marker for disease relapse, which oc-
curs in most patients. Considering that the induction 
of a second remission is associated to high therapeutic 
failure8, chemotherapy changes before relapse could 
help control cancer progression13.
The acute phase response associated to canine 
lymphoma was described in some studies. Increased 
levels of C-reactive protein3,12,15, serum amyloid A13, 
a1-acid glycoprotein16, and haptoglobin3,15 had previ-
ously been detected in dogs with lymphoma before 
the chemotherapy, suggesting that the disease is a 
true stimulus for the hepatic synthesis of these pro-
teins, similarly to what is observed in inflammatory 
conditions not related to cancer. Furthermore, levels 
of C-reactive protein12, serum amyloid A13, and a1-
acid glycoprotein16 gradually decreased in dogs that 
underwent chemotherapy and achieved a complete or 
partial remission, confirming the role of lymphoma 
itself on triggering the acute phase response. Cerulo-
plasmin is considered a positive acute phase protein, 
whose concentration usually increases upon stimu-
lation by proinflammatory cytokines2. In this study, 
levels of ceruloplasmin in dogs with lymphoma prior 
to the chemotherapy were no higher than the levels 
observed in healthy dogs prior to the chemotherapy, 
what disagrees with the behavior of other positive 
acute phase proteins in canine lymphoma. Normal 
values of ceruloplasmin concentration in canine se-
rum are 14,9 ± 2,6 UI/L, and, under inflammatory 
conditions, 20 UI/L17. Although ceruloplasmin is 
somewhat more specific than other acute phase pro-
teins because it remains stable during steroid therapy, 
inflammation could lead to an increasing of only 50%, 
what clearly compromises its usefulness on accessing 
mild inflammatory conditions. In the only study in 
which ceruloplasmin was determined in the serum of 
canine patients with hematologic neoplasias (leukemia 
and lymphoma), there was no statistically significant 
difference between the levels observed in healthy and 
sick dogs3. These results coupled with the lack of in-
duction of ceruloplasmin in our study suggest that it 
should not be used alone to evaluate the acute phase 
response in dogs with lymphoma. In this context, some 
authors postulate that ceruloplasmin is a moderate 
positive acute phase protein in dogs and cats owing to 
the low magnitude of response in inflammatory pro-
cesses18. Indeed, ceruloplasmin should be determined 
in conjunction to a major acute phase protein like C-
reactive protein and serum amyloid A in the dog or 
a1-acid glycoprotein and serum amyloid A in the cat18 . 
Ceruloplasmin levels could be higher at the lym-
phoma relapse because of a new synthesis of acute 
phase proteins incited by volumetric expansion of the 
tumors (lymph nodes, spleen, and liver). However, 
levels of ceruloplasmin experienced a progressive de-
WEEKS OF TREATMENT
GROUPS
                       Control (n = 10)                                                    ML (n = 13)
1 (before treatment) 17.85 ± 5.45 21.67 ± 7.69
4 (remission evaluation) 19.87 ± 7.54 13.76 ± 5.79 
Relapse ... 14.26 ± 5.93  
Table 1 - Mean values and standard deviation of ceruloplasmin serum concentration (UI/L) during 
chemotherapeutic treatment in control and multicentric lymphoma (ML) groups, according 
weeks of treatment - São Paulo - 2008
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cline after starting the chemotherapy and kept above 
the pre-treatment values for both healthy and lym-
phoma dogs. In similar trials regarding the monitor-
ing of dogs with lymphoma, abnormally elevated pre-
chemotherapy values of C-reactive protein12, serum 
amyloid A13, and a1-acid glycoprotein 16 decreased 
following the treatment. Surprisingly, in this study 
ceruloplasmin declineat both in clinical remission 
and in relapse; its levels were lower than prior to the 
chemotherapy. This finding suggests chemotherapy 
influenced ceruloplasmin synthesis in dogs irrespec-
tively of the presence of lymphoma. Taking into ac-
count ceruloplasmin contains eigt8 atoms of copper 
per molecule2, a possible mechanism involving cupric 
metabolism could be involved. In a report, dogs with 
lymphoma exhibited lower levels of copper in ceru-
loplasmin (-22%) and iron in tranferrin (-33%) than 
healthy animals19. Indeed, following treatment of dogs 
with doxorubicin and l-asparaginase, plasma concen-
tration of copper and iron reduced even more, -18% 
and -13%, respectively, what favors the hypothesis of 
chemotherapy leading to changes in ceruloplasmin 
levels. As dogs in this study were assigned to proto-
cols without doxorubicin, the influence of other che-
motherapies on copper metabolism for justifying ce-
ruloplasmin decreasing should be further evaluated. 
Considering the hepatic synthesis of Cp, dogs with 
lymphoma showed changes in the serum activity of 
liver enzymes at diagnosis, which decreased with the 
beginning of treatment, but at no time during treat-
ment showed other signs such as low albumin levels 
or jaundice to indicate greater impairment liver and 
could be justify the low levels of ceruloplasmin.
Finally, previous studies failed to identify an effect of 
chemotherapy itself on C-reactive protein and serum 
amyloid A concentrations in healthy dogs12,13. Some-
how, this fact favors the possibility of ceruloplasmin 
be influenced indirectly by plasma levels of copper, as 
the mentioned proteins do not contain copper in their 
molecular structures. 
In conclusion, ceruloplasmin levels remain un-
changed in dogs with multicentric lymphoma at the 
disease diagnosis, and chemotherapy induces a de-
crease in ceruloplasmin levels in both healthy animals 
and in animals with lymphoma. The lack of induction 
by lymphoma and the influence by chemotherapy 
make ceruloplasmin an inappropriate acute phase 
protein for the monitoring of canine lymphoma. 
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